Novartis AG (NVS)

NYSE - Nasdaq Real-time price. Currency in USD

Add to watchlist

85.85

-0.25

(-0.29%)

At close: 04:00PM EST

86.25

+0.40

(+0.47%)

After hours:

06:40PM EST

Loading interactive chart…

Simply Wall St.
Novartis (VTX:NOVN) Is Paying Out A Larger Dividend Than Last Year
Novartis AG's ( VTX:NOVN ) dividend will be increasing from last year's payment of the same period to $3.20 on 13th of...
GlobeNewswire
Patients with hidradenitis suppurativa experienced sustained efficacy and symptom improvement at one year when treated with Novartis Cosentyx®
In two of the largest Phase III trials conducted in hidradenitis suppurativa (HS), Cosentyx® (secukinumab) treatment response rates continued to improve beyond the primary endpoint analysis at Week 16 to more than 55% at Week 52, as evaluated by the HS Clinical Response (HiSCR) measure1 Safety findings were consistent with the well-established safety profile of Cosentyx in its approved indications1 HS is a recurrent skin disease affecting one in 100 people worldwide, causing painful, boil-like a
Simply Wall St.
Novartis Full Year 2022 Earnings: Misses Expectations
Novartis ( VTX:NOVN ) Full Year 2022 Results Key Financial Results Revenue: US$51.8b (down 2.0% from FY 2021). Net...